Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4513398 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPK1LMNAGLAHSD17B10 | |
| SCHEMBL5946021 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPK1LMNAGLAHSD17B10 | |
| SCHEMBL19385118 | 0.89 | GAA (0.35) | ALDH1A1MAPK1LMNAHPGDTSHR | |
| SCHEMBL22555636 | 0.89 | GAA (0.35) | ALDH1A1MAPK1LMNAHPGDTSHR | |
| SCHEMBL22555635 | 0.89 | GAA (0.35) | ALDH1A1MAPK1LMNAHPGDTSHR | |
| SCHEMBL19385119 | 0.89 | GAA (0.35) | ALDH1A1MAPK1LMNAHPGDTSHR | |
| SCHEMBL29064415 | 0.89 | GAA (0.35) | ALDH1A1MAPK1LMNAHPGDTSHR | |
| SCHEMBL25363482 | 0.82 | ALDH1A1 (0.57) | ALDH1A1MAPK1LMNAGLAHSD17B10 | |
| SCHEMBL2224391 | 0.82 | ALDH1A1 (0.57) | ALDH1A1MAPK1LMNAGLAHSD17B10 | |
| SCHEMBL28774060 | 0.82 | ALDH1A1 (0.57) | ALDH1A1MAPK1LMNAGLAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444225-B1 | PYRROLIDINE OXADIAZOLE- AND THIADIAZOLE OXIME DERIVATIVES BEING OXYTOCIN RECEPTOR ANTAGONISTS. | MERCK SERONO SA (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-20090264425-A1 | CHEMICAL COMPOUNDS | PFIZER LIMITED | 2009-10-22 | — | — | US | disclosed |
| EP-1831157-A2 | NONNUCLEOSIDE INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | Pfizer Limited (GB) | 2007-09-12 | — | — | EP | disclosed |
| US-20060229343-A1 | Pyrrolidine oxadiazole-and thiadiazole oxime derivatives being oxytocin receptor antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDDING N.V. (NL) | 2006-10-12 | — | — | US | disclosed |
| US-7115639-B2 | Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-10-03 | — | — | US | disclosed |
| WO-2006067587-A2 | NONNUCLEOSIDE INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | PFIZER LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| US-20040220238-A1 | Pyrrolidine oxadiazole-and thiadiazole derivatives | MERCK SERONO SA (CH) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220238-A1 | Pyrrolidine oxadiazole-and thiadiazole derivatives | OXTR, PRLHR, PGF | ALDH1A1 1541/4885MAPK1 3216/4885LMNA 3441/4885 |
| US-20060229343-A1 | Pyrrolidine oxadiazole-and thiadiazole oxime derivatives being oxytocin receptor antagonists | OXTR, PRLHR, OXER1 | ALDH1A1 2144/4885MAPK1 2748/4885LMNA 3805/4885 |
| US-20090264425-A1 | CHEMICAL COMPOUNDS | POLR2E, POLR2A, POLRMT | ALDH1A1 423/4885MAPK1 4190/4885LMNA 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.